Strategy for Extending Half-life in Drug Design and Its Significance
Autor: | Hakan Gunaydin, Scott A. Johnson, Brian R. Lahue, Blair T. Lapointe, J. Michael Ellis, Michael D. Altman, Peter Fuller |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Drug Chemistry media_common.quotation_subject Organic Chemistry Half-life Pharmacology 030226 pharmacology & pharmacy Biochemistry 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Drug Discovery Lipophilicity Dose prediction Potency Constant (mathematics) media_common |
Zdroj: | ACS Medicinal Chemistry Letters. 9:528-533 |
ISSN: | 1948-5875 |
DOI: | 10.1021/acsmedchemlett.8b00018 |
Popis: | [Image: see text] Preclinical optimization of compounds toward viable drug candidates requires an integrated understanding of properties that impact predictions of the clinically efficacious dose. The importance of optimizing half-life, unbound clearance, and potency and how they impact dose predictions are discussed in this letter. Modest half-life improvements for short half-life compounds can dramatically lower the efficacious dose. The relationship between dose and half-life is nonlinear when unbound clearance is kept constant, whereas the relationship between dose and unbound clearance is linear when half-life is kept constant. Due to this difference, we show that dose is more sensitive to changes in half-life than changes in unbound clearance when half-lives are shorter than 2 h. Through matched molecular pair analyses, we also show that the strategic introduction of halogens is likely to increase half-life and lower projected human dose even though increased lipophilicity does not guarantee extended half-life. |
Databáze: | OpenAIRE |
Externí odkaz: |
načítá se...